Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Irinotecan +/- Capecitabine in Elderly Metastatic Colorectal Cancer
NCT00303745Phase 2Unknown
- Sponsor
- Fédération Francophone de Cancérologie Digestive
- Start
- Jun 2006
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of capecitabine in colorectal cancer (CRC) (2 arms), sponsored by Fédération Francophone de Cancérologie Digestive. Primary endpoints: Objective Response Rate and Stable Disease Rate. Status: unknown.
02
Drugs
capecitabine
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT00303745.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00303745.